Optimizing -lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?

被引:83
|
作者
Delattre, Isabelle K. [1 ,2 ]
Taccone, Fabio S. [3 ]
Jacobs, Frederique [4 ]
Hites, Maya [4 ]
Dugernier, Thierry [5 ]
Spapen, Herbert [6 ]
Laterre, Pierre-Francois [7 ]
Wallemacq, Pierre E. [2 ]
Van Bambeke, Francoise [1 ]
Tulkens, Paul M. [1 ]
机构
[1] Catholic Univ Louvain, Louvain Drug Res Inst, Brussels, Belgium
[2] Clin Univ St Luc, Dept Clin Chem, Brussels, Belgium
[3] Hop Erasme, Dept Intens Care, Brussels, Belgium
[4] Hop Erasme, Dept Infect Dis, Brussels, Belgium
[5] Clin St Pierre, Dept Intens Care, Ottignies, Belgium
[6] Univ Ziekenhuis Brussel, Dept Intens Care, Brussels, Belgium
[7] Clin Univ St Luc, Dept Intens Care, Brussels, Belgium
关键词
B-lactams; critically-ill patients; PK; PD targets; first dose; maximal efficacy; CARE-UNIT PATIENTS; MINIMUM INHIBITORY CONCENTRATION; FEBRILE NEUTROPENIC PATIENTS; RENAL REPLACEMENT THERAPY; CONTINUOUS VENOVENOUS HEMODIAFILTRATION; STEADY-STATE PHARMACOKINETICS; DEFINING ANTIBIOTIC LEVELS; MORBIDLY OBESE-PATIENTS; LOWER RESPIRATORY-TRACT; POPULATION PHARMACOKINETICS;
D O I
10.1080/14787210.2017.1338139
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: The pharmacokinetic/pharmacodynamic index determining -lactam activity is the percentage of the dosing interval (%T) during which their free serum concentration remains above a critical threshold over the minimum inhibitory concentration (MIC). Regrettably, neither the value of %T nor that of the threshold are clearly defined for critically-ill patients.Areas covered: We review and assess the targets proposed for -lactams in critical illness by screening the literature since 1997. Depending on the study intention (clinical cure vs. suppression of resistance), targets proposed range from 20%T>1xMIC to 100%T>5xMIC. Assessment and comparative analysis of their respective clinical efficacy suggest that a value of 100%T>4xMIC may be needed. Simulation studies, however, show that this target will not be reached at first dose for the majority of critically-ill patients if using the most commonly recommended doses.Expert commentary: Considering that critically-ill patients are highly vulnerable and likely to experience antibiotic underexposure, and because effective initial treatment is a key determinant of clinical outcome, we support the use of a target of 100%T>4xMIC, which could not only maximize efficacy but also minimize emergence of resistance. Clinical and microbiological studies are needed to test for the feasibility and effectiveness of reaching such a demanding target.
引用
收藏
页码:677 / 688
页数:12
相关论文
共 9 条
  • [1] Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients
    Wagner, BKJ
    O'Hara, DA
    CLINICAL PHARMACOKINETICS, 1997, 33 (06) : 426 - 453
  • [2] Pharmacokinetics and Pharmacodynamics of Sedatives and Analgesics in the Treatment of Agitated Critically Ill Patients
    Bertil Wagner
    Dorene A. O’Hara
    Clinical Pharmacokinetics, 1997, 33 : 426 - 453
  • [3] Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg
    Szalek, E.
    Tomczak, H.
    Kaminska, A.
    Grabowski, T.
    Smuszkiewicz, P.
    Matysiak, K.
    Wolc, A.
    Kaczmarek, Z.
    Grzeskowiak, E.
    ADVANCES IN MEDICAL SCIENCES, 2012, 57 (02): : 217 - 223
  • [4] Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review
    Sinnollareddy, Mahipal
    Peake, Sandra L.
    Roberts, Michael S.
    Lipman, Jeffrey
    Roberts, Jason A.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2012, 39 (01) : 1 - 10
  • [5] PHARMACOKINETICS AND PHARMACODYNAMICS OF ANTIMICROBIALS IN CRITICALLY ILL PATIENTS WITH LOWER RESPIRATORY TRACT INFECTIONS. ARE 'ONE SIZE FITS ALL' DOSES APPROPRIATE?
    Oldfield, I. B.
    Kipper, K.
    Barker, C. I.
    Philips, B. J.
    Cecconi, M.
    Rhodes, A.
    Johnston, A.
    Standing, J. F.
    Baker, E. H.
    Sharland, M.
    Lonsdale, D. O.
    THORAX, 2016, 71 : A9 - A10
  • [6] Population Pharmacokinetics of Fluconazole in Critically Ill Patients Receiving Continuous Venovenous Hemodiafiltration: Using Monte Carlo Simulations To Predict Doses for Specified Pharmacodynamic Targets
    Patel, Kashyap
    Roberts, Jason A.
    Lipman, Jeffrey
    Tett, Susan E.
    Deldot, Megan E.
    Kirkpatrick, Carl M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (12) : 5868 - 5873
  • [7] First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis
    Roberts, Jason A.
    Kirkpatrick, Carl M. J.
    Roberts, Michael S.
    Dalley, Andrew J.
    Lipman, Jeffrey
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2010, 35 (02) : 156 - 163
  • [8] Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation
    Bakdach, Dana
    Elajez, Reem
    Bakdach, Abdul Rahman
    Awaisu, Ahmed
    De Pascale, Gennaro
    Hssain, Ali Ait
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (23)
  • [9] Vancomycin Area under the Curve and Pharmacokinetic Parameters during the First 24 Hours of Treatment in Critically Ill Patients using Bayesian Forecasting
    Pongchaidecha, Manat
    Changpradub, Dhitiwat
    Bannalung, Kanjana
    Seejuntra, Kajeewan
    Thongmee, Sutthanuch
    Unnual, Aminta
    Santimaleeworagun, Wichai
    INFECTION AND CHEMOTHERAPY, 2020, 52 (04): : 573 - 582